Altered Interleukin-1 Receptor Antagonist and Interleukin-18 mRNA Expression in Myocardial Tissues of Patients with Dilatated Cardiomyopathy

Table 1 Patient data

	Control	ICM	DCM
n	9	8	10
Sex, M/F	6/3	6/2	9/1
Age, years	42.6 ± 14.5	53.9 ±6.6	50.1 ± 9.2
Hemodynamics EF, %		25.0 ± 1.0	26.0 ± 8.0
NYHA grade		3.5 ±0.2	3.7 ±0.2
Heart rate, bpm		83.0 ± 7.0	80.0 ± 8.0
PCW, mmHg		16.0 ±3.0	20.0 ±3.0
MAP, mmHg		75.0 ± 2.0	79.0 ± 2.0
Cardiac index		2.5 ± 0.5	2.0 ±0.2
Comorbidity, n Atrial fibrillation		1	7
Hypertension		4^a	1
Diabetes		4	1
Hyperlipidemia		5	2
Pre-explantation treatments, n
Beta-blockers		5	7
Glycoside		4	8
Other antiarrhythmics		1	3
Anticoagulation		5	10
ACE inhibitor/AT1 blocker		8	9
Nitrate		7	6
Lipid-lowering drug		5	2

^aHypertension was not relevant for cardiac failure according to the judgments of the treating physician and the explanting surgeon. ACE, angiotensin converting enzyme; AT1, angiotensin II type 1 receptor; EF, ejection fraction; MAP, mean arterial pressure; NYHA, New York Heart Association score; PCW, pulmonary capillary wedge pressure.

ISSN: 1528-3658